Apellis Pharmaceuticals, Inc. (APLS) financial statements (2021 and earlier)

Company profile

Business Address 100 FIFTH AVENUE
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments878352176176
Cash and cash equivalents566352176176
Short-term investments312   
Restricted cash and investments1   
Prepaid expense1120245
Other current assets27100
Other undisclosed current assets  11
Total current assets:917373202182
Noncurrent Assets
Operating lease, right-of-use asset1814
Property, plant and equipment72  
Other noncurrent assets19010
Total noncurrent assets:431610
TOTAL ASSETS:961389204182
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12063157
Accounts payable88104
Accrued liabilities1125553
Debt 32 
Other undisclosed current liabilities8   
Total current liabilities:12866177
Noncurrent Liabilities
Long-term debt and lease obligation3741541920
Long-term debt, excluding current maturities3591431920
Operating lease, liability1512
Liabilities, other than long-term debt  77
Due to related parties  77
Other undisclosed noncurrent liabilities23813500
Total noncurrent liabilities:6282892627
Total liabilities:7563554333
Stockholders' equity
Stockholders' equity attributable to parent20534161149
Common stock0000
Additional paid in capital1,131616438298
Accumulated other comprehensive loss(0)(0)(0) 
Accumulated deficit(926)(581)(277)(149)
Total stockholders' equity:20534161149
TOTAL LIABILITIES AND EQUITY:961389204182

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Gross profit:251   
Operating expenses(464)(288)(128)(51)
Operating loss:(214)(288)(128)(51)
Nonoperating income4530
Investment income, nonoperating453 
Other nonoperating income (expense)(1)(0)(0)0
Interest and debt expense (2)  
Other undisclosed loss from continuing operations before equity method investments, income taxes(133)(20)  
Loss from continuing operations before income taxes:(343)(305)(125)(51)
Income tax expense(2)   
Loss before gain (loss) on sale of properties:(345)(305)(125)(51)
Other undisclosed net loss  (2) 
Net loss:(345)(305)(128)(51)
Other undisclosed net loss attributable to parent   (0)
Net loss available to common stockholders, diluted:(345)(305)(128)(51)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(345)(305)(128)(51)
Other comprehensive income0   
Comprehensive loss:(345)(305)(128)(51)
Other undisclosed comprehensive loss, net of tax, attributable to parent (0)(0) 
Comprehensive loss, net of tax, attributable to parent:(345)(305)(128)(51)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: